Skip to main content
SpringerLink
Log in

Mutant Epitopes in Cancer

  • Chapter
  • First Online:
Oncoimmunology

Abstract

Targeted immunotherapy in cancer is a rapidly expanding and evolving field with a developmental history spanning at least three decades. Beginning with the identification and characterisation of tumour-specific antigens (TSA)—protein molecules which are exclusively present on the surface of cancer cells—and very recently the dawn of neoantigen-specific immune-cell reactivity—championed by immune checkpoint blockade therapy—demonstrates that immune-based interventions will shape the future of cancer therapy. Neoantigens arise from naturally processed host protein molecules—eventually presented as immunogenic peptides to the immune system. However, a deeper understanding concerning the generation and recognition of neoantigens is indispensable in order to better understand the immunological and biological underpinnings in diagnostics and therapeutic applications in to enhance healthcare for patients with cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017;17(4):209–22.

    Article  CAS  PubMed  Google Scholar 

  2. Sharpe M, Mount N. Genetically modified T cells in cancer therapy: opportunities and challenges. Dis Model Mech. 2015;8(4):337–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R, Reddy KR, et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One. 2013;8(5):e63818.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. 2006;12(10):1198–202.

    Article  CAS  PubMed  Google Scholar 

  6. Singh A, Dey AB, Mohan A, Mitra DK. Programmed death-1 receptor suppresses gamma-IFN producing NKT cells in human tuberculosis. Tuberculosis. 2014;94(3):197–206.

    Article  CAS  PubMed  Google Scholar 

  7. Wykes MN, Horne-Debets JM, Leow CY, Karunarathne DS. Malaria drives T cells to exhaustion. Front Microbiol. 2014;5:249.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Abbas A, Lichtman A, Pilai S. Basic immunology: functions and disorders of the immune system. Philadelphia: Elsevier Saunders; 2014.

    Google Scholar 

  9. Hammerling GJ. The 1996 Nobel Prize to Rolf Zinkernagel and Peter Doherty. Cell Tissue Res. 1997;287(1):1–2.

    CAS  PubMed  Google Scholar 

  10. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature. 1974;248(5450):701–2.

    Article  CAS  PubMed  Google Scholar 

  11. Zinkernagel RM, Doherty PC. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature. 1974;251(5475):547–8.

    Article  CAS  PubMed  Google Scholar 

  12. Zinkernagel RM, Doherty PC. The discovery of MHC restriction. Immunol Today. 1997;18(1):14–7.

    Article  CAS  PubMed  Google Scholar 

  13. Brighenti S, Andersson J. Induction and regulation of CD8+ cytolytic T cells in human tuberculosis and HIV infection. Biochem Biophys Res Commun. 2010;396(1):50–7.

    Article  CAS  PubMed  Google Scholar 

  14. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res. 1998;58(21):4902–8.

    CAS  PubMed  Google Scholar 

  15. Valmori D, Fonteneau JF, Valitutti S, Gervois N, Dunbar R, Lienard D, et al. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int Immunol. 1999;11(12):1971–80.

    Article  CAS  PubMed  Google Scholar 

  16. Zarling AL, Ficarro SB, White FM, Shabanowitz J, Hunt DF, Engelhard VH. Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J Exp Med. 2000;192(12):1755–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207(3):637–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Tian Y, Sette A, Weiskopf D. Cytotoxic CD4 T cells: differentiation, function, and application to dengue virus infection. Front Immunol. 2016;7:531.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer. 1997;72(5):784–90.

    Article  CAS  PubMed  Google Scholar 

  20. Delgado JC, Baena A, Thim S, Goldfeld AE. Aspartic acid homozygosity at codon 57 of HLA-DQ beta is associated with susceptibility to pulmonary tuberculosis in Cambodia. J Immunol. 2006;176(2):1090–7.

    Article  CAS  PubMed  Google Scholar 

  21. Dorman JS, Bunker CH. HLA-DQ locus of the human leukocyte antigen complex and type 1 diabetes mellitus: a HuGE review. Epidemiol Rev. 2000;22(2):218–27.

    Article  CAS  PubMed  Google Scholar 

  22. Kaushansky N, Altmann DM, David CS, Lassmann H, Ben-Nun A. DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP). J Neuroinflammation. 2012;9:29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bandaru A, Devalraju KP, Paidipally P, Dhiman R, Venkatasubramanian S, Barnes PF, et al. Phosphorylated STAT3 and PD-1 regulate IL-17 production and IL-23 receptor expression in Mycobacterium tuberculosis infection. Eur J Immunol. 2014;44(7):2013–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Perreau M, Rozot V, Welles HC, Belluti-Enders F, Vigano S, Maillard M, et al. Lack of Mycobacterium tuberculosis-specific interleukin-17A-producing CD4+ T cells in active disease. Eur J Immunol. 2013;43(4):939–48.

    Article  CAS  PubMed  Google Scholar 

  25. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautes-Fridman C, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood. 2002;99(6):2114–21.

    Article  CAS  PubMed  Google Scholar 

  26. Fabre J, Giustiniani J, Garbar C, Antonicelli F, Merrouche Y, Bensussan A, et al. Targeting the tumor microenvironment: the protumor effects of IL-17 related to cancer type. Int J Mol Sci. 2016;17(9):E1433.

    Article  PubMed  CAS  Google Scholar 

  27. Liang H, Yi L, Wang X, Zhou C, Xu L. Interleukin-17 facilitates the immune suppressor capacity of high-grade glioma-derived CD4 (+) CD25 (+) Foxp3 (+) T cells via releasing transforming growth factor beta. Scand J Immunol. 2014;80(2):144–50.

    Article  CAS  PubMed  Google Scholar 

  28. Xiang T, Long H, He L, Han X, Lin K, Liang Z, et al. Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer. Oncogene. 2015;34(2):165–76.

    Article  CAS  PubMed  Google Scholar 

  29. Sloan-Lancaster J, Shaw AS, Rothbard JB, Allen PM. Partial T cell signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy. Cell. 1994;79(5):913–22.

    Article  CAS  PubMed  Google Scholar 

  30. Lorvik KB, Hammarstrom C, Fauskanger M, Haabeth OA, Zangani M, Haraldsen G, et al. Adoptive transfer of tumor-specific Th2 cells eradicates tumors by triggering an in situ inflammatory immune response. Cancer Res. 2016;76(23):6864–76.

    Article  CAS  PubMed  Google Scholar 

  31. Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med. 1999;190(5):617–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Zhang L, Ge C, Zhao F, Zhang Y, Wang X, Yao M, et al. NRBP2 overexpression increases the chemosensitivity of hepatocellular carcinoma cells via Akt signaling. Cancer Res. 2016;76(23):7059–71.

    Article  CAS  PubMed  Google Scholar 

  33. Shen Y, Fujimoto S. A tumor-specific Th2 clone initiating tumor rejection via primed CD8+ cytotoxic T-lymphocyte activation in mice. Cancer Res. 1996;56(21):5005–11.

    CAS  PubMed  Google Scholar 

  34. Mattes J, Hulett M, Xie W, Hogan S, Rothenberg ME, Foster P, et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med. 2003;197(3):387–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Haabeth OA, Bogen B, Corthay A. A model for cancer-suppressive inflammation. Oncoimmunology. 2012;1(7):1146–55.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306.

    Article  CAS  PubMed  Google Scholar 

  37. Qian F, Gnjatic S, Jager E, Santiago D, Jungbluth A, Grande C, et al. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. Cancer Immun. 2004;4:12.

    PubMed  Google Scholar 

  38. Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet. 2009;41(5):591–5.

    Article  CAS  PubMed  Google Scholar 

  39. Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinform. 2010;11:568.

    Article  CAS  Google Scholar 

  40. Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, et al. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol. 2005;174(3):1751–9.

    Article  CAS  PubMed  Google Scholar 

  41. Fallang LE, Bergseng E, Hotta K, Berg-Larsen A, Kim CY, Sollid LM. Differences in the risk of celiac disease associated with HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen presentation. Nat Immunol. 2009;10(10):1096–101.

    Article  CAS  PubMed  Google Scholar 

  42. Sidney J, Steen A, Moore C, Ngo S, Chung J, Peters B, et al. Five HLA-DP molecules frequently expressed in the worldwide human population share a common HLA supertypic binding specificity. J Immunol. 2010;184(5):2492–503.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Hovhannisyan Z, Weiss A, Martin A, Wiesner M, Tollefsen S, Yoshida K, et al. The role of HLA-DQ8 beta57 polymorphism in the anti-gluten T-cell response in coeliac disease. Nature. 2008;456(7221):534–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Siebold C, Hansen BE, Wyer JR, Harlos K, Esnouf RE, Svejgaard A, et al. Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Proc Natl Acad Sci U S A. 2004;101(7):1999–2004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Ettinger RA, Kwok WW. A peptide binding motif for HLA-DQA1*0102/DQB1*0602, the class II MHC molecule associated with dominant protection in insulin-dependent diabetes mellitus. J Immunol. 1998;160(5):2365–73.

    CAS  PubMed  Google Scholar 

  46. Shukla SA, Rooney MS, Rajasagi M, Tiao G, Dixon PM, Lawrence MS, et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. 2015;33(11):1152–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Lurquin C, Van Pel A, Mariame B, De Plaen E, Szikora JP, Janssens C, et al. Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell. 1989;58(2):293–303.

    Article  CAS  PubMed  Google Scholar 

  48. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254(5038):1643–7.

    Article  PubMed  Google Scholar 

  49. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med. 1995;182(3):689–98.

    Article  PubMed  Google Scholar 

  50. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994;180(1):35–42.

    Article  CAS  PubMed  Google Scholar 

  51. Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A. 2001;98(18):10290–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997;94(5):1914–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998;187(2):265–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Neumann F, Wagner C, Kubuschok B, Stevanovic S, Rammensee HG, Pfreundschuh M. Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. Cancer Immunol Immunother. 2004;53(7):589–99.

    Article  CAS  PubMed  Google Scholar 

  55. Jager E, Karbach J, Gnjatic S, Jager D, Maeurer M, Atmaca A, et al. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. Cancer Immun. 2002;2:12.

    PubMed  Google Scholar 

  56. Gnjatic S, Nishikawa H, Jungbluth AA, Gure AO, Ritter G, Jager E, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006;95:1–30.

    Article  CAS  PubMed  Google Scholar 

  57. Hosken NA, Bevan MJ. Defective presentation of endogenous antigen by a cell line expressing class I molecules. Science. 1990;248(4953):367–70.

    Article  CAS  PubMed  Google Scholar 

  58. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med. 1995;181(2):799–804.

    Article  CAS  PubMed  Google Scholar 

  59. Wang RF, Johnston SL, Southwood S, Sette A, Rosenberg SA. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J Immunol. 1998;160(2):890–7.

    CAS  PubMed  Google Scholar 

  60. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science. 1999;284(5418):1351–4.

    Article  CAS  PubMed  Google Scholar 

  61. Wang RF, Wang X, Rosenberg SA. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J Exp Med. 1999;189(10):1659–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996;93(1):136–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7(12):3862–8.

    CAS  PubMed  Google Scholar 

  64. Chang K, Pastan I. Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line. Int J Cancer. 1994;57(1):90–7.

    Article  CAS  PubMed  Google Scholar 

  65. Suarez-Alvarez B, Garcia Suarez MM, Arguelles ME, Sampedro A, Alvarez Marcos C, Mira E, et al. Circulating IgG response to stromelysin-3, collagenase-3, galectin-3 and mesothelin in patients with pharynx/larynx squamous cell carcinoma. Anticancer Res. 2001;21(5):3677–84.

    CAS  PubMed  Google Scholar 

  66. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrom KE, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A. 1999;96(20):11531–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, Pastan I. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J Immunother. 2000;23(4):473–9.

    Article  CAS  PubMed  Google Scholar 

  68. Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol. 1995;25(2):340–7.

    Article  CAS  PubMed  Google Scholar 

  69. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A. 1995;92(17):7976–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995;269(5228):1281–4.

    Article  CAS  PubMed  Google Scholar 

  71. Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med. 1997;186(5):785–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Burmer GC, Loeb LA. Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. Proc Natl Acad Sci U S A. 1989;86(7):2403–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Chiosea SI, Sherer CK, Jelic T, Dacic S. KRAS mutant allele-specific imbalance in lung adenocarcinoma. Mod Pathol. 2011;24(12):1571–7.

    Article  CAS  PubMed  Google Scholar 

  75. Hartman DJ, Davison JM, Foxwell TJ, Nikiforova MN, Chiosea SI. Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival. Int J Cancer. 2012;131(8):1810–7.

    Article  CAS  PubMed  Google Scholar 

  76. Krasinskas AM, Moser AJ, Saka B, Adsay NV, Chiosea SI. KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas. Mod Pathol. 2013;26(10):1346–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Kranenburg O. The KRAS oncogene: past, present, and future. Biochim Biophys Acta. 2005;1756(2):81–2.

    CAS  PubMed  Google Scholar 

  78. YC L, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res. 2014;20(13):3401–10.

    Article  CAS  Google Scholar 

  79. Hoffmann TK, Loftus DJ, Nakano K, Maeurer MJ, Chikamatsu K, Appella E, et al. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope. J Immunol. 2002;168(3):1338–47.

    Article  CAS  PubMed  Google Scholar 

  80. Jameson SC, Hogquist KA, Bevan MJ. Positive selection of thymocytes. Annu Rev Immunol. 1995;13:93–126.

    Article  CAS  PubMed  Google Scholar 

  81. Evavold BD, Allen PM. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science. 1991;252(5010):1308–10.

    Article  CAS  PubMed  Google Scholar 

  82. Evavold BD, Sloan-Lancaster J, Hsu BL, Allen PM. Separation of T helper 1 clone cytolysis from proliferation and lymphokine production using analog peptides. J Immunol. 1993;150(8 Pt 1):3131–40.

    CAS  PubMed  Google Scholar 

  83. Bertoletti A, Sette A, Chisari FV, Penna A, Levrero M, De Carli M, et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature. 1994;369(6479):407–10.

    Article  CAS  PubMed  Google Scholar 

  84. Spain LM, Jorgensen JL, Davis MM, Berg LJ. A peptide antigen antagonist prevents the differentiation of T cell receptor transgenic thymocytes. J Immunol. 1994;152(4):1709–17.

    CAS  PubMed  Google Scholar 

  85. Sprent J, Tough DF. Lymphocyte life-span and memory. Science. 1994;265(5177):1395–400.

    Article  CAS  PubMed  Google Scholar 

  86. Tran E, Robbins PF, YC L, Prickett TD, Gartner JJ, Jia L, et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016;375(23):2255–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Daniels MA, Teixeiro E. TCR signaling in T cell memory. Front Immunol. 2015;6:617.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  88. Kaech SM, Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol. 2012;12(11):749–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Restifo NP, Gattinoni L. Lineage relationship of effector and memory T cells. Curr Opin Immunol. 2013;25(5):556–63.

    Article  CAS  PubMed  Google Scholar 

  90. Zehn D, Lee SY, Bevan MJ. Complete but curtailed T-cell response to very low-affinity antigen. Nature. 2009;458(7235):211–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Sabatino JJ Jr, Huang J, Zhu C, Evavold BD. High prevalence of low affinity peptide-MHC II tetramer-negative effectors during polyclonal CD4+ T cell responses. J Exp Med. 2011;208(1):81–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. D’Souza WN, Hedrick SM. Cutting edge: latecomer CD8 T cells are imprinted with a unique differentiation program. J Immunol. 2006;177(2):777–81.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Knudson KM, Goplen NP, Cunningham CA, Daniels MA, Teixeiro E. Low-affinity T cells are programmed to maintain normal primary responses but are impaired in their recall to low-affinity ligands. Cell Rep. 2013;4(3):554–65.

    Article  CAS  PubMed  Google Scholar 

  94. Teixeiro E, Daniels MA, Hamilton SE, Schrum AG, Bragado R, Jameson SC, et al. Different T cell receptor signals determine CD8+ memory versus effector development. Science. 2009;323(5913):502–5.

    Article  CAS  PubMed  Google Scholar 

  95. Morita CT, Jin C, Sarikonda G, Wang H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol Rev. 2007;215:59–76.

    Article  CAS  PubMed  Google Scholar 

  96. Gogoi D, Chiplunkar SV. Targeting gamma delta T cells for cancer immunotherapy: bench to bedside. Indian J Med Res. 2013;138(5):755–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  97. Gertner-Dardenne J, Bonnafous C, Bezombes C, Capietto AH, Scaglione V, Ingoure S, et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood. 2009;113(20):4875–84.

    Article  CAS  PubMed  Google Scholar 

  98. Todaro M, D’Asaro M, Caccamo N, Iovino F, Francipane MG, Meraviglia S, et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol. 2009;182(11):7287–96.

    Article  CAS  PubMed  Google Scholar 

  99. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197(2):163–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Nada MH, Wang H, Workalemahu G, Tanaka Y, Morita CT. Enhancing adoptive cancer immunotherapy with Vgamma2Vdelta2 T cells through pulse zoledronate stimulation. J Immunother Cancer. 2017;5:9.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Zhang H, Hu H, Jiang X, He H, Cui L, He W. Membrane HSP70: the molecule triggering gammadelta T cells in the early stage of tumorigenesis. Immunol Investig. 2005;34(4):453–68.

    Article  CAS  Google Scholar 

  102. Laad AD, Thomas ML, Fakih AR, Chiplunkar SV. Human gamma delta T cells recognize heat shock protein-60 on oral tumor cells. Int J Cancer. 1999;80(5):709–14.

    Article  CAS  PubMed  Google Scholar 

  103. Tran E, Robbins PF, Rosenberg SA. ‘Final common pathway’ of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol. 2017;18(3):255–62.

    Article  CAS  PubMed  Google Scholar 

  104. Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph-Pietras D, et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med. 2014;6(254):254ra128.

    Article  PubMed  CAS  Google Scholar 

  105. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74.

    Article  CAS  PubMed  Google Scholar 

  107. van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013;31(32):e439–42.

    Article  PubMed  Google Scholar 

  108. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016;22:433.

    Article  CAS  PubMed  Google Scholar 

  110. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Kowalewski DJ, Stevanovic S, Rammensee HG, Stickel JS. Antileukemia T-cell responses in CLL—we don’t need no aberration. Oncoimmunology. 2015;4(7):e1011527.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  112. Luo YH, CH W, WS W, Huang CY, WJ S, Tsai CM, et al. Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs. J Thorac Oncol. 2012;7(2):299–305.

    Article  CAS  PubMed  Google Scholar 

  113. Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015;16(9):e447–59.

    Article  CAS  PubMed  Google Scholar 

  114. Azuma K, Komatsu N, Hattori S, Matsueda S, Kawahara A, Sasada T, et al. Humoral immune responses to EGFR-derived peptides predict progression-free and overall survival of non-small cell lung cancer patients receiving gefitinib. PLoS One. 2014;9(1):e86667.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  115. Yamada T, Azuma K, Muta E, Kim J, Sugawara S, Zhang GL, et al. EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation. PLoS One. 2013;8(11):e78389.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Sasada T, Azuma K, Ohtake J, Fujimoto Y. Immune responses to epidermal growth factor receptor (EGFR) and their application for cancer treatment. Front Pharmacol. 2016;7:405.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Evavold BD, Sloan-Lancaster J, Allen PM. Antagonism of superantigen-stimulated helper T-cell clones and hybridomas by altered peptide ligand. Proc Natl Acad Sci U S A. 1994;91(6):2300–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Kersh EN, Kersh GJ, Allen PM. Partially phosphorylated T cell receptor zeta molecules can inhibit T cell activation. J Exp Med. 1999;190(11):1627–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Seitzer U, Kayser K, Hohn H, Entzian P, Wacker HH, Ploetz S, et al. Reduced T-cell receptor CD3zeta-chain protein and sustained CD3epsilon expression at the site of mycobacterial infection. Immunology. 2001;104(3):269–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 1992;258(5089):1795–8.

    Article  CAS  PubMed  Google Scholar 

  121. Finke JH, Zea AH, Stanley J, Longo DL, Mizoguchi H, Tubbs RR, et al. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993;53(23):5613–6.

    CAS  PubMed  Google Scholar 

  122. Frydecka I, Kaczmarek P, Bocko D, Kosmaczewska A, Morilla R, Catovsky D. Expression of signal-transducing zeta chain in peripheral blood T cells and natural killer cells in patients with Hodgkin’s disease in different phases of the disease. Leuk Lymphoma. 1999;35(5-6):545–54.

    Article  CAS  PubMed  Google Scholar 

  123. Valkenburg SA, Gras S, Guillonneau C, La Gruta NL, Thomas PG, Purcell AW, et al. Protective efficacy of cross-reactive CD8+ T cells recognising mutant viral epitopes depends on peptide-MHC-I structural interactions and T cell activation threshold. PLoS Pathog. 2010;6(8):e1001039.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  124. Tureci O, Vormehr M, Diken M, Kreiter S, Huber C, Sahin U. Targeting the heterogeneity of cancer with individualized neoepitope vaccines. Clin Cancer Res. 2016;22(8):1885–96.

    Article  CAS  PubMed  Google Scholar 

  125. Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A. 2015;112(6):1809–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. van der Windt GJ, Everts B, Chang CH, Curtis JD, Freitas TC, Amiel E, et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity. 2012;36(1):68–78.

    Article  PubMed  CAS  Google Scholar 

  129. Perna SK, De Angelis B, Pagliara D, Hasan ST, Zhang L, Mahendravada A, et al. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res. 2013;19(1):106–17.

    Article  CAS  PubMed  Google Scholar 

  130. Waldmann TA. Interleukin-15 in the treatment of cancer. Expert Rev Clin Immunol. 2014;10(12):1689–701.

    Article  CAS  PubMed  Google Scholar 

  131. Floros T, Tarhini AA. Anticancer cytokines: biology and clinical effects of interferon-alpha2, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol. 2015;42(4):539–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Meng Q, Liu Z, Rangelova E, Poiret T, Ambati A, Rane L, et al. Expansion of tumor-reactive T cells from patients with pancreatic cancer. J Immunother. 2016;39(2):81–9.

    Article  CAS  PubMed  Google Scholar 

  133. Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, et al. The IL-15-based ALT-803 complex enhances FcgammaRIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas. Clin Cancer Res. 2016;22(3):596–608.

    Article  CAS  PubMed  Google Scholar 

  134. Weng J, Moriarty KE, Baio FE, Chu F, Kim S-D, He J, et al. IL-15 enhances the anti-tumor effect of human antigen-specific CD8 T cells by cellular senescence delay. Oncoimmunology. 2016. 5(12):e1237327.

    Google Scholar 

  135. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol. 2009;156(1):149–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014;257(1):56–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Ebert LM, MacRaild SE, Zanker D, Davis ID, Cebon J, Chen W. A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. PLoS One. 2012;7(10):e48424.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Fourcade J, Sun Z, Kudela P, Janjic B, Kirkwood JM, El-Hafnawy T, et al. Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire. J Immunol. 2010;184(12):6709–18.

    Article  CAS  PubMed  Google Scholar 

  139. Roychoudhuri R, Eil RL, Clever D, Klebanoff CA, Sukumar M, Grant FM, et al. The transcription factor BACH2 promotes tumor immunosuppression. J Clin Invest. 2016;126(2):599–604.

    Article  PubMed  PubMed Central  Google Scholar 

  140. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. de Witte MA, Coccoris M, Wolkers MC, van den Boom MD, Mesman EM, Song JY, et al. Targeting self-antigens through allogeneic TCR gene transfer. Blood. 2006;108(3):870–7.

    Article  PubMed  CAS  Google Scholar 

  142. Linnemann C, Heemskerk B, Kvistborg P, Kluin RJ, Bolotin DA, Chen X, et al. High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med. 2013;19(11):1534–41.

    Article  CAS  PubMed  Google Scholar 

  143. Winograd EK, Ciesielski MJ, Fenstermaker RA. Novel vaccines for glioblastoma: clinical update and perspective. Immunotherapy. 2016;8(11):1293–308.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Fremd C, Schuetz F, Sohn C, Beckhove P, Domschke C. B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology. 2013;2(7):e25443.

    Article  PubMed  PubMed Central  Google Scholar 

  145. Chaudhary B, Khaled YS, Ammori BJ, Elkord E. Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol Immunother. 2014;63(2):81–99.

    Article  CAS  PubMed  Google Scholar 

  146. Nahtman T, Jernberg A, Mahdavifar S, Zerweck J, Schutkowski M, Maeurer M, et al. Validation of peptide epitope microarray experiments and extraction of quality data. J Immunol Methods. 2007;328(1-2):1–13.

    Article  CAS  PubMed  Google Scholar 

  147. Ngo Y, Advani R, Valentini D, Gaseitsiwe S, Mahdavifar S, Maeurer M, et al. Identification and testing of control peptides for antigen microarrays. J Immunol Methods. 2009;343(2):68–78.

    Article  CAS  PubMed  Google Scholar 

  148. Reilly M, Valentini D. Visualisation and pre-processing of peptide microarray data. Methods Mol Biol. 2009;570:373–89.

    Article  CAS  PubMed  Google Scholar 

  149. Valentini D, Rao M, Ferrara G, Perkins M, Dodoo E, Zumla A, et al. Immune recognition surface construction of Mycobacterium tuberculosis epitope-specific antibody responses in tuberculosis patients identified by peptide microarrays. Int J Infect Dis. 2017;56:155–66.

    Article  CAS  PubMed  Google Scholar 

  150. Valentini D, Gaseitsiwe S, Maeurer M. Humoral ‘reactome’ profiles using peptide microarray chips. Trends Immunol. 2010;31(11):399–400.

    Article  CAS  PubMed  Google Scholar 

  151. Valentini D, Ferrara G, Advani R, Hallander HO, Maeurer MJ. Serum reactome induced by Bordetella pertussis infection and pertussis vaccines: qualitative differences in serum antibody recognition patterns revealed by peptide microarray analysis. BMC Immunol. 2015;16:40.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  152. Gaseitsiwe S, Valentini D, Mahdavifar S, Magalhaes I, Hoft DF, Zerweck J, et al. Pattern recognition in pulmonary tuberculosis defined by high content peptide microarray chip analysis representing 61 proteins from M. tuberculosis. PLoS One. 2008;3(12):e3840.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  153. Gaseitsiwe S, Valentini D, Mahdavifar S, Reilly M, Ehrnst A, Maeurer M. Peptide microarray-based identification of Mycobacterium tuberculosis epitope binding to HLA-DRB1*0101, DRB1*1501, and DRB1*0401. Clin Vaccine Immunol. 2010;17(1):168–75.

    Article  CAS  PubMed  Google Scholar 

  154. Ambati A, Valentini D, Montomoli E, Lapini G, Biuso F, Wenschuh H, et al. H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix vaccination. Immunology. 2015;145(3):357–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  155. Perez-Bercoff L, Valentini D, Gaseitsiwe S, Mahdavifar S, Schutkowski M, Poiret T, et al. Whole CMV proteome pattern recognition analysis after HSCT identifies unique epitope targets associated with the CMV status. PLoS One. 2014;9(4):e89648.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  156. Gaseitsiwe S, Valentini D, Ahmed R, Mahdavifar S, Magalhaes I, Zerweck J, et al. Major histocompatibility complex class II molecule-human immunodeficiency virus peptide analysis using a microarray chip. Clin Vaccine Immunol. 2009;16(4):567–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  157. Ferrara G, Valentini D, Rao M, Wahlstrom J, Grunewald J, Larsson LO, et al. Humoral immune profiling of mycobacterial antigen recognition in sarcoidosis and Lofgren’s syndrome using high-content peptide microarrays. Int J Infect Dis. 2017;56:167.

    Article  CAS  PubMed  Google Scholar 

  158. WHO. World cancer report 2014. Lyon: International Agency for Research on Cancer, World Health Organisation; 2014.

    Google Scholar 

  159. Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8(3):173–83.

    Article  PubMed  PubMed Central  Google Scholar 

  160. Karbach J, Gnjatic S, Pauligk C, Bender A, Maeurer M, Schultze JL, et al. Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination. Int J Cancer. 2007;121(9):2042–8.

    Article  CAS  PubMed  Google Scholar 

  161. Chen JL, Dawoodji A, Tarlton A, Gnjatic S, Tajar A, Karydis I, et al. NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus. Int J Cancer. 2015;136(6):E590–601.

    Article  CAS  PubMed  Google Scholar 

  162. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21(8):914–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  163. Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21(5):1019–27.

    Article  CAS  PubMed  Google Scholar 

  164. Fonteneau JF, Brilot F, Munz C, Gannage M. The tumor antigen NY-ESO-1 mediates direct recognition of melanoma cells by CD4+ T cells after intercellular antigen transfer. J Immunol. 2016;196(1):64–71.

    Article  CAS  PubMed  Google Scholar 

  165. Jacquelot N, Enot DP, Flament C, Vimond N, Blattner C, Pitt JM, et al. Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. J Clin Invest. 2016;126(3):921–37.

    Article  PubMed  PubMed Central  Google Scholar 

  166. Munson DJ, Egelston CA, Chiotti KE, Parra ZE, Bruno TC, Moore BL, et al. Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR. Proc Natl Acad Sci U S A. 2016;113(29):8272–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  167. Sims JS, Grinshpun B, Feng Y, Ung TH, Neira JA, Samanamud JL, et al. Diversity and divergence of the glioma-infiltrating T-cell receptor repertoire. Proc Natl Acad Sci U S A. 2016;113(25):E3529–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Gilchuk P, Spencer CT, Conant SB, Hill T, Gray JJ, Niu X, et al. Discovering naturally processed antigenic determinants that confer protective T cell immunity. J Clin Invest. 2013;123(5):1976–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  169. Tran E, Turcotte S, Gros A, Robbins PF, YC L, Dudley ME, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641–5.

    Article  CAS  PubMed  Google Scholar 

  170. Tran E, Ahmadzadeh M, YC L, Gros A, Turcotte S, Robbins PF, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350(6266):1387–90.

    Article  CAS  PubMed  Google Scholar 

  171. Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K. Trebska-McGowan K, Bliskovsky VV, et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest. 2015;125(10):3981–91.

    Article  PubMed  PubMed Central  Google Scholar 

  172. Reshef R, Luskin MR, Kamoun M, Vardhanabhuti S, Tomaszewski JE, Stadtmauer EA, et al. Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. Am J Transplant. 2011;11(4):817–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  173. Subklewe M, Marquis R, Choquet S, Leblond V, Garnier JL, Hetzer R, et al. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation. Transplantation. 2006;82(8):1093–100.

    Article  CAS  PubMed  Google Scholar 

  174. Pourfarziani V, Einollahi B, Taheri S, Nemati E, Nafar M, Kalantar E. Associations of human leukocyte antigen (HLA) haplotypes with risk of developing lymphoproliferative disorders after renal transplantation. Ann Transplant. 2007;12(4):16–22.

    PubMed  Google Scholar 

  175. Bertoletti A, Brunetto M, Maini MK, Bonino F, Qasim W, Stauss H. T cell receptor-therapy in HBV-related hepatocellularcarcinoma. Oncoimmunology. 2015;4(6):e1008354.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  176. Stronen E, Toebes M, Kelderman S, van Buuren MM, Yang W, van Rooij N, et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science. 2016;352(6291):1337–41.

    Article  CAS  PubMed  Google Scholar 

  177. Dvorak CC, Gilman AL, Horn B, Jaroscak J, Dunn EA, Baxter-Lowe LA, et al. Clinical and immunologic outcomes following haplocompatible donor lymphocyte infusions. Bone Marrow Transplant. 2009;44(12):805–12.

    Article  CAS  PubMed  Google Scholar 

  178. Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dossinger G, Schiemann M, et al. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. Leukemia. 2017.

    Google Scholar 

  179. Mennonna D, Maccalli C, Romano MC, Garavaglia C, Capocefalo F, Bordoni R, et al. T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes. Gut. 2017;66(3):454–63.

    Article  PubMed  Google Scholar 

  180. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21(1):15–25.

    Article  CAS  PubMed  Google Scholar 

  181. Wang LX, Mei ZY, Zhou JH, Yao YS, Li YH, YH X, et al. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses. PLoS One. 2013;8(5):e62924.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  182. Fan H, Lu X, Wang X, Liu Y, Guo B, Zhang Y, et al. Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report. J Immunol Res. 2014;2014:371087.

    PubMed  PubMed Central  Google Scholar 

  183. Siva S, MacManus MP, Martin RF, Martin OA. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett. 2015;356(1):82–90.

    Article  CAS  PubMed  Google Scholar 

  184. Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med. 2013;2(6):899–906.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  185. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  186. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  187. D’Souza NM, Fang P, Logan J, Yang J, Jiang W, Li J. Combining radiation therapy with immune checkpoint blockade for central nervous system malignancies. Front Oncol. 2016;6:212.

    Article  PubMed  PubMed Central  Google Scholar 

  188. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174(12):7516–23.

    Article  CAS  PubMed  Google Scholar 

  189. Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 2008;181(5):3099–107.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  190. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  191. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  192. Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer. 2016;4:51.

    Article  PubMed  PubMed Central  Google Scholar 

  193. Cohen JV, Kluger HM. Systemic immunotherapy for the treatment of brain metastases. Front Oncol. 2016;6:49.

    Article  PubMed  PubMed Central  Google Scholar 

  194. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  195. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62–8.

    Article  CAS  PubMed  Google Scholar 

  196. Chen YY. Efficient gene editing in primary human T cells. Trends Immunol. 2015;36(11):667–9.

    Article  CAS  PubMed  Google Scholar 

  197. Arsenio J, Metz PJ, Chang JT. Asymmetric cell division in T lymphocyte fate diversification. Trends Immunol. 2015;36(11):670–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  198. Gollwitzer ES, Marsland BJ. Impact of early-life exposures on immune maturation and susceptibility to disease. Trends Immunol. 2015;36(11):684–96.

    Article  CAS  PubMed  Google Scholar 

  199. Wertek F, Xu C. Digital response in T cells: to be or not to be. Cell Res. 2014;24(3):265–6.

    Article  PubMed  PubMed Central  Google Scholar 

  200. Huang J, Brameshuber M, Zeng X, Xie J, Li QJ, Chien YH, et al. A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4(+) T cells. Immunity. 2013;39(5):846–57.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Therapeutic Immunology Unit (TIM), Department of Laboratory Medicine (LABMED), Karolinska Institutet, Stockholm, Sweden

    Martin Rao, Liu Zhenjiang, Qingda Meng, Ernest Dodoo & Markus Maeurer

  2. Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden

    Georges Sinclair & Ernest Dodoo

  3. Center for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge, Stockholm, Sweden

    Markus Maeurer

Authors
  1. Martin Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liu Zhenjiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qingda Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Georges Sinclair
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ernest Dodoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Markus Maeurer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Maeurer .

Editor information

Editors and Affiliations

  1. Gustave Roussy Cancer Center , Villejuif Cedex, France

    Laurence Zitvogel

  2. Gustave Roussy Cancer Center , Villejuif Cedex, France

    Guido Kroemer

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rao, M., Zhenjiang, L., Meng, Q., Sinclair, G., Dodoo, E., Maeurer, M. (2018). Mutant Epitopes in Cancer. In: Zitvogel, L., Kroemer, G. (eds) Oncoimmunology. Springer, Cham. https://doi.org/10.1007/978-3-319-62431-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-62431-0_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-62430-3

  • Online ISBN: 978-3-319-62431-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation